Biomarkers Increase R&D Success Rates, Preempt Failures, & Reduce Cost

By Doug Graham, Life Science Leader magazine

Drugs don’t debut quickly or cheaply. A new treatment develops over a decade or more, at a cost just south of a billion dollars. Pharma is business as well as science and, like any industry, must routinely cope with pressures imposed by economic uncertainty, increasing competition, and tighter regulation.

Only recently has the global economy begun its long crawl to recovery, which some experts claim may grind to a halt soon. Healthcare reform, an Obama administration prime directive, will likely complicate the pharma universe further still, as it will bring on ramifications highly significant to the industry.